Ticagrelor was associated with lower all-cause mortality compared to clopidogrel but similar rates of MI, stroke, and bleeding. Prasugrel showed similar rates for all studied outcomes compared to clopidogrel. There was also more switching of therapy and less persistence in patients initially on novel P2Y12 inhibitors. Here, P2RY12 is linked to Stroke.